基托桑水凝与MK2抑制剂载纳米颗粒一起用于治疗亚托邦皮肤炎
Vanessa F C Dartora1, Julia Sapienza Passos2, Blanca Osorio3
1Biomedical Engineering Graduate Group, University of California Davis, Davis, CA, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, USA.
概括
一种装载着携带MK2抑制剂 (YARA) 的纳米颗粒的新型酸水凝显示出对治疗阿托皮性皮炎 (AD) 的希望. 这种配方增强了药物到皮肤的传递,并显著减少了炎症性细胞因子,为目前的治疗提供了潜在的替代方案.
科学领域:
- 生物材料科学 生物材料科学
- 皮肤病学 皮肤病学
- 纳米技术 纳米技术
背景情况:
- 亚托皮炎 (AD) 是一种慢性炎症性皮肤疾病,由于现有疗法的副作用,长期治疗选择有限.
- 目前对中度至重度阿尔茨海默病的治疗方法通常会导致诸如皮肤缩等不良影响.
研究的目的:
- 开发和评估一种用于治疗亚托皮炎的新型局部配方.
- 为了研究含有YARA装载纳米颗粒的奇托水凝对增强药物递送和抗炎活性的疗效.
主要方法:
- 雅拉被装入热响应纳米粒子 (NP).
- 纳米颗粒被纳入了奇托水凝 (H-NP-YARA).
- 评估了药物加载效率,水凝多孔性 (SEM),YARA释放动力学,体外皮肤透以及对角质细胞和体外皮肤模型的抗炎作用.
主要成果:
- H-NP-YARA表现出高的YARA加载效率 (>50%) 和持续释放长达120小时.
- 该配方与非封装化合物相比,显著增强了YARA在猪皮层中的传递.
- 用YARA载荷NP和H-NP-YARA治疗显著降低了细胞和体外皮肤模型中的炎症性细胞因子水平 (IL-1β,IL-6,TNF-α).
结论:
- 含有YARA载荷纳米颗粒的奇托水凝是用于局部AD治疗的有希望的配方.
- H-NP-YARA系统改善了局部药物输送,并具有显著的抗炎性质.
- 这种新的配方为管理中度至重度的亚托皮性皮肤炎提供了潜在的替代方案.
更多相关视频
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...